rivaroxaban + clopidogrel

Rivaroxaban + clopidogrel is a combination of two oral antithrombotic agents used together for enhanced prevention of thrombotic events in certain cardiovascular conditions. Rivaroxaban is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, thereby interrupting the coagulation cascade and reducing thrombin generation and clot formation. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 subtype of ADP receptor on platelets, preventing platelet aggregation. This dual therapy targets both platelet activation and the coagulation pathway, offering comprehensive protection against arterial thrombosis. The combination has been studied as an alternative to traditional dual antiplatelet therapy (DAPT) or triple therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI), those with peripheral artery disease (PAD) after revascularization, and other high-risk cardiovascular populations[1][2][3][7]. Clinical studies suggest this regimen may reduce major adverse limb events without significantly increasing major bleeding risk compared to some standard regimens[2][3].

Other names

rivaroxaban plus clopidogrel